Hemostemix Inc.
HEM
Kedudukan dalam Saham
#32563
Hemostemix Inc., a clinical stage biotechnology company, develops,... Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.
Harga Saham
$0.04403621
Disegerakkan terakhir: 2026-10-16
Modal Pasaran
$9.31M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
-40.80%
Negara
CA
Perdagangan Hemostemix Inc. (HEM)
Kategori
Healthcare
Modal pasaran bagi Hemostemix Inc.(HEM)
Modal Pasaran: $9.31M
Sehingga October 2026, Hemostemix Inc. mempunyai modal pasaran sebanyak $9.31M. Ini menjadikan Hemostemix Inc. syarikat ke-32563rd paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Hemostemix Inc. dari 2005 hingga 2026
HEM berbanding dengan 5 teratas yang paling popular stocks
